A United States indication for duvelisib in previously treated relapsed/refractory follicular lymphoma has been voluntarily withdrawn by developer Secura Bio following an assessment of the drug and subsequent consultation with the FDA.
The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.
Cell therapy omidubicel, designed for patients with hematologic malignancies who are undergoing allogeneic stem cell transplant, will be submitted to the FDA for approval in 2022.
The single-cell functional precision medicine treatment, an artificial intelligence strategy helps to create therapies for patients with hematologic cancers.
Older patients undergoing treatment for B-cell malignancies who contracted the COVID-19 virus were at an increased risk of death vs patients with other cancers under the age of 60 years.
The FDA issued a complete response letter to the company responsible for developing narsoplimab because of the inability to estimate treatment effects on patients receiving hematopoietic stem cell transplant–associated thrombotic microangiopathy.
There remains a therapeutic challenge with understanding and treating patients with accelerated myeloproliferative neoplasms.
Findings from the phase 1 CARBON trial indicated that patients with relapsed/refractory CD19-positive B-cell malignancies may benefit from CTX110 CAR T-cell therapy.
Results from a cohort study found that the rate of late mortality has decreased over the last 40 years for patients who transplantation at a younger age or who received a bone marrow transplant.
Clinical trials featuring rusfertide may resume dosing patients after the FDA lifted a full clinical hold on the therapy’s clinical studies.